Biomedical Sciences Research Centre Seminar Series
Towards the development of a HAGE-based vaccine for the treatment of breast cancer

As part of the School of Science and Technology Biomedical Sciences Research Centre Seminar Series, Divya Nagarajan, Nottingham Trent University, presents: Towards the development of a HAGE-based vaccine for the treatment of breast cancer.
- From: Wednesday 8 November 2017, 1.10 pm
- To: Wednesday 8 November 2017, 2 pm
- Location: ERD 282, Nottingham Trent University, Clifton Campus, Clifton Lane, Nottingham, NG11 8NS
- Download this event to your calendar
Event details
As part of the School of Science and Technology Biomedical Sciences Research Centre Seminar Series, Divya Nagarajan, Nottingham Trent University, presents: Towards the development of a HAGE-based vaccine for the treatment of breast cancer.
Abstract
TNBC is the most aggressive form of breast cancer with higher relapse rates and poor prognosis. Chemotherapy has improved survival rates of cancer patients over recent years, with however no significant clinical benefit for metastatic disease. Immunotherapy on the other hand could target metastatic cells and generate a long and durable immune response. The immune system can be educated, via the use of a vaccine, to recognise and kill TNBC cells expressing many proteins that are either unique or differentially regulated compared to normal cells. HAGE (CT13, DDX43) protein has been found to be expressed in 47% of TNBC and to be immunogenic. During this presentation, the immunogenicity and anti-tumour efficacy of HAGE-derived vaccines will be discussed. Overall, the results achieved so far demonstrate the value of HAGE-derived vaccines for the treatment HAGE positive cancers, paving the way for the development of a phase-I clinical trial.
All welcome.
This seminar is hosted by Stephanie McArdle.
For any enquiries please contact Dr Amanda Coutts or Dr John Dickenson.
Location details
Address:
Clifton Campus
Clifton Lane
Nottingham
NG11 8NS
Past event